No one ever climbed the industry ladder without getting some help along the way. And for women, including many of the accomplished top performers in this group, that can be especially important. Maybe it was an encouraging nudge for a bright young scientist or a willing mentor for a rising company player--but virtually everyone in this year's group of top women in biotech benefited from a higher-up's helping hand.
Now, these women are re-gifting that upward boost to the next generation of leaders. Some are actively involved in nonprofit groups aiming to inspire women in business. Others single out promising younger women who might benefit from their guidance and experienced counsel.
This year's Class of 2013 includes entrepreneurs running biotechs, raising cash and advancing new drugs in the clinic. Read the full report >>
The Hatch-Waxman Act shook up the generic drugs business in 1984, and almost 30 years later, it's safe to say the law had its desired effect. About 84% of the 4 billion prescriptions written each year are for generic drugs, saving patients and government programs billions of dollars a year. In other words, generic drugs are big business. And with a slew of blockbuster brands now off patent, it's a big business with growing pains.
As companies bulked up to take on copies of the world's best-selling drugs, a wave of mergers has swept the industry. Many credit Actavis CEO Paul Bisaro with starting that trend; then the Watson CEO, his 2012 takeover of Actavis sent a clear message of "go big or go home" reverberating throughout the generics business. Actavis hasn't stopped scouting for deals, and many of its peers have followed suit.
Peruse the Top 10 to find out how these trends and market forces are shaping the industry's biggest players--and vice versa. Read the report >>
It seemed like a match made in heaven. A few years ago, as the patent cliff neared and drugmakers were looking for new sources of revenue, market researchers were toting up growth prospects around the world. The answer, for both, was emerging markets. Drug spending would more or less stagnate in mature markets such as the United States and the European Union. But in the developing world, drug spending was just taking off.
Like miners rushing to California in the 1880s, drugmakers raced to capture their share of those markets. While cutting costs, shuttering facilities and laying off thousands in the U.S. and EU, pharma companies hired on in China, India, Mexico--to the point where laid-off sales reps joked about moving to Asia to find a pharma job. Read the full report >>
Have something to say? Join other pharma
executives on FiercePharma's LinkedIn group.
POPULAR COMMENT THREADS
In the 25 years since the first World AIDS Day, patient outcomes have improved significantly, but the long-sought-after vaccine remains elusive. As the world commemorated the event this week, two very different projects outlined their plans to combat the virus.
When MedImmune won approval for its quadrivalent nasal flu vaccine back in February 2012, it kicked off the battle to claim a share of the next-generation influenza immunization market. Now, almost two years later, its parent company AstraZeneca has the race underway in Europe, too.
Vaccines have basically worked the same way for decades. A pathogen antigen is isolated, used as the basis of a vaccine and administered to the patient. The Pentagon thinks there might be a better way of doing things, and it has tasked Pfizer with investigating its hunch.
PaxVax has raised $22 million in venture capital funding to advance development of its oral cholera vaccine, PXVX0200. The investment gives PaxVax the cash to run a 3,000-patient Phase III trial of the product.
Princeton University will not begin to offer Novartis' meningitis B vaccine to Bexsero to students until next week, but health officials are already considering expanding the campaign to another university. An outbreak at the University of California, Santa Barbara, is the cause of the latest concerns.
A lack of exposure to infections early in life is one of many proposed contributing factors to development of multiple sclerosis. With this in mind, some have questioned whether giving the immune system a light workout could stave off the autoimmune disorder.
From Our Sister Sites
Two years and $100 million removed from a devastating FDA roadblock, Orexigen Therapeutics is again knocking on the agency's door with its weight loss drug Contrave, filing an NDA with fresh hopes it win approval and succeed in a tough market.
Ireland is balking at proposed tougher medical device regulations in the European Union, a major voice of opposition as member states work to hash out a final law.